Vitasora Health Limited · ASX:VHL

Vitasora Health — Shareholder Meeting (November 2022)

15 slides from Vitasora Health's shareholder meeting presentation, Nov 15, 2022

  1. Slide 1: Presentation to Shareholders at 2022 AGM

    15th November 2022 ASX ANNOUNCEMENT ASX: RSH ASX Market Announcements Platform Sydney NSW PRESENTATION TO SHAREHOLDERS AT 2022 AGM BY NICHOLAS SMEDLEY (CHAIR) AND MARJAN MIKEL (CEO/MD) Respiri Limited (ASX:RSH)(“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health manage

  2. Slide 2: A Medical Devices & SaaS Company

    A Medical Devices & SaaS Company CONFIDENTIAL: This material should not be copied or distributed without the permission of Respiri Limited. Nicholas Smedley (Chair) and Marjan Mikel (CEO & MD) FDA cleared Class II Medical Device AGM 15 Nov 2022 ASX:RSH, OTCQB:RSHUF

  3. Slide 3: Forward Looking

    Forward Looking Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri’s current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and a

  4. Slide 4: Executive Summary

    Executive Summary Market Dynamics  ~50M Americans living with COPD or Asthma,  $134.3Bn financial burden  30-day COPD re-admission rates as high as 38%.  Medicare fines institutions who don’t meet targets (~50% in 2020) Remote Patient Monitoring (RPM)  AGR 30%+ to USD85B by 2026  RPM fee sched

  5. Slide 5: Creating scalable and sustainable growth

    Creating scalable and sustainable growth delivering shareholder value FY23 FY24 FY25 OBJECTIVE: OBJECTIVE: OBJECTIVE: Onboard first US customers; Multiple contracted customers; Profitable; Scale wearable; New Wearable clinical development Sustainable growth; Break-even revenue streams run-rate, Laun

  6. Slide 6: Respiratory Disease: A significant burden to the US healthcare system

    Respiratory Disease: A significant burden to the US healthcare system Addressable market The problem  Respiratory disease represents a $134.3Bn financial burden on the ~50M Americans health system (COPD#/Asthma)  Re-admission rates continue to put strain on US Health System, with 30- day COPD re-a

  7. Slide 7: Remote Patient Monitoring: our solution is world class and proven

    Remote Patient Monitoring our solution is world class and proven  Medicare reimbursement for RPM grew by 588% (CY20/19)  For every healthcare provider, there are ~20 patients billed at least once  Avg, Medicare payment/per patient generates >$738, upside can be >$ 1,750 per patient.  Wheezo addr

  8. Slide 8: Current Procedural Terminology (CPT)

    Current Procedural Terminology (CPT) Established and economically favorable RPM CPT Code Descriptor Fees 99453 Patient set up (once per episode of care) Device delivery/supply 99454 (every 30 days, min.16 days of data collection) Provider sets patient up on a Physiological data Data sent in real tim

  9. Slide 9: wheezo major RPM programs

    wheezo® major RPM programs Imminent first patients onboarded Customers RPM Program description Michigan Children’s Hospital Integrating wheezo® RPM program into standard of care part of DMC; owned by NYSE:THC (60 like hospitals) for paediatric patients living with Asthma North Carolina First Phase:

  10. Slide 10: A scalable end-to-end solution

    A scalable end-to-end solution Secure Cloud Storage PATIENTS HEALTHCARE PROVIDERS wheezo® respiriTM app Health Portal Healthcare Breath sensor Patient-user interface Clinical Staff Organizations FDA cleared Class II Algorithm detects abnormal breath sounds  Access patient data ACOs, HMOs, Clinical

  11. Slide 11: Innovative, Unique & Easy

    Innovative, Unique & Easy WheezeRate Detector: (device) and app detect wheeze by analysing breath sounds from a 30 second breath recording and returns a WheezeRate wheezo® respiri™ app device Breath patient (user) interface Sensor Records breath sounds Detects abnormal breath sounds & History of Whe

  12. Slide 12: Research & Development

    Research & Development Innovation from Admission to follow-up Market potential Current Status  Need for continuous monitoring of physiological  First prototype has been assembled and undergoing initial parameters is highly regarded across the US health testing system  Reliable data-acquisition sy

  13. Slide 13: US Business overview

    US Business overview Metrics, controlled launch, strong pipeline.  Revenue generated by monthly ARR ~$20 & devices (30-40% margins);  Breakeven 30k to 40k active patients  First patients onboarded across our initial customer base; reimbursement pending in December 2022  Major RPM customers secur

  14. Slide 14: Respiri Limited Risk Factors

    Disclaimer statement This report identifies some of the major risks associated with an investment in the Company. The risk factors below ought not to be taken as exhaustive of the risks faced by the Company or by investors in the Company. Speculative nature of investment: An investment in Shares of

  15. Slide 15: Thank You.

    Thank You. Marjan Mikel, CEO& MD Marjan@respiri.co +61 408 462 873 Respiri Limited (ASX:RSH, OTCQB:RSHUF)

Vitasora Health — Shareholder Meeting (November 2022) on 6ix